Developer docs
API playgroundTry for free, no card

Search company profiles

PIRCHE

Full company profile

uuid003xq19

Namestring
PIRCHE
Legal namestring
Pirche AG
Websiteurl
pirche.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

PIRCHE AG is a Berlin-headquartered digital diagnostics company founded in 2014 that builds the TxPredictor platform, described as an Immune Intelligence Platform for transplantation medicine. The company's core technology predicts how a recipient's immune system will recognize and respond to donor organ HLA epitopes using proprietary T-cell epitope matching (PIRCHE-I for CD8+ and PIRCHE-II for CD4+ responses) and B-cell epitope matching via the Snow algorithm, both powered by AI neural networks trained on HLA binding motifs. The platform processes genetic typing data on a high-performance cloud infrastructure and integrates with major HLA laboratory IT systems, offering six functional modules (RAMP, Tmem, Outcomes Prediction, Donor Selection, HSCT Search Profile) that support donor selection, immunosuppression management, and post-transplant surveillance for solid organ and stem cell transplantation, as well as emerging use cases in cell therapy and immuno-oncology.

The company commercializes TxPredictor as a subscription SaaS product through three access tiers (Routine, Research, Demo) sold via enterprise field sales targeting transplant centers and HLA laboratories globally. Distribution is augmented by integration partnerships — notably with Werfen (MatchX API), Natera (companion prognostics combining PIRCHE scores with Prospera dd-cfDNA monitoring), and Mayo Clinic for clinical validation — alongside educational partnerships with AST, TTC, and GenDx. PIRCHE cites more than 1 million real-world transplant cases processed and 200+ peer-reviewed publications supporting clinical utility. The company is privately held as a German Aktiengesellschaft, maintains a US regional office in Walpole, Massachusetts, has a small leadership team, and is actively soliciting external investment.

Short descriptiontext

PIRCHE AG operates the TxPredictor platform, an AI-powered HLA epitope matching system that helps transplant centers predict donor-recipient immune compatibility, guide immunosuppression, and monitor post-transplant risk for solid organ and stem cell grafts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HLA epitope matching, transplant immunology, donor-recipient matching, immunological risk assessment, transplant compatibility software
Industry1 code
PRIMARYHLACAMAL
Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Transplant Immunology Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1TxPredictor Platform Subscription
TypeSubscription Recurring
Description

PIRCHE operates as a SaaS platform (TxPredictor) providing molecular HLA epitope matching services to transplant centers and HLA laboratories. The platform is offered through a cloud-based subscription model with different access levels including routine access, research access, and demo access.

pirche.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Platform access tiers for different user needs
ModelSubscriptionBilling cadenceAnnual
Notes

Three access tiers available: Routine Access (clinical use), Research Access (research purposes), and Demo Access. Specific pricing not publicly disclosed.

pirche.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

PIRCHE develops and sells the TxPredictor platform, a cloud-based Immune Intelligence Platform that uses AI-supported immunological simulations to predict how a recipient's immune system will recognize and respond to donor organ HLA epitopes. The platform combines T cell epitope matching (PIRCHE-I and PIRCHE-II) with B cell epitope matching (Snow algorithm) to quantify pre-transplant immunologic risk, support donor selection, guide immunosuppression, and enable personalized post-transplant surveillance for solid organ and stem cell transplant centers and HLA laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Low PIRCHE score can help rule out development of harmful antibodies 94.2% of the time (Santos et al.)
+2 more records
Product overview1 text field

PIRCHE offers a platform-plus-modules architecture centered on the TxPredictor platform, the world's first Immune Intelligence Platform. The platform uses AI neural networks to analyze genetic HLA typing data and predict immunogenicity scores for transplant compatibility assessment. The product portfolio includes six modules: RAMP (Risk and Acceptable Mismatch Profile) for donor selection and immunosuppression management, Tmem for T-cell memory response modeling, Outcomes Prediction for clinical risk assessment, Donor Selection for multi-donor comparison, and HSCT Search Profile for stem cell donor identification. The platform integrates predictive PIRCHE immunogenicity scores with real-time dd-cfDNA injury detection through companion prognostics partnerships, transforming transplant care from reactive damage control to proactive precision surveillance.

Product and service6 records
1TxPredictor
CategoryCore Platform
Description

The world's first Immune Intelligence Platform that merges genetic typing with AI-supported immunological simulations, enabling clinicians and HLA laboratories to make precise, personalized medical decisions for transplant patients. Runs on high-performance cloud infrastructure with real-time analysis, integration with major HLA vendors' software, absolute and relative immunologic risk quantification, and low turnaround time.

2RAMP (Risk and Acceptable Mismatch Profile)
CategoryPlatform Module
Description

Module supporting informed donor selection, immunosuppression management, and post-transplant monitoring by predicting epitope mismatches at the locus level. Allows users to evaluate how individual mismatches contribute to overall PIRCHE-T2 and PIRCHE-B scores and match donor populations to patients.

3Tmem (T Memory)
CategoryPlatform Module
Description

Module modeling T-cell memory responses that standard HLA testing cannot detect. Uses previous immunizer data to provide insight into potential post-transplant antibody risks by identifying HLA mismatches the immune system may have encountered before, distinguishing typical unacceptable mismatches from those associated with prior immune activation.

4Outcomes Prediction Module (OPM)
CategoryPlatform Module
Description

Module providing transplant teams with comprehensive understanding of factors influencing transplant outcomes by incorporating key clinical variables such as patient age, race, prior transplants alongside HLA molecular matching data. Available through the Early Access Program.

5Donor Selection Module
CategoryPlatform Module
Description

Tool supporting both solid organ and stem cell transplantation by allowing clinicians to compare multiple donors for a single patient using comprehensive immune profiling. Evaluates immunologic compatibility in real time with color-coded heatmaps highlighting which HLA mismatches most strongly contribute to total immunogenicity.

6HSCT Search Profile
CategoryPlatform Module
Description

Module designed for hematopoietic stem cell transplant teams to identify low-epitope-mismatched HLA combinations even without access to a full stem cell donor registry. Estimates likelihood of finding a donor with a low PIRCHE score and presents data in combined table and chart view.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-19
Description

Strategic collaboration to advance transplant medicine by combining pre-transplant immunological risk assessment using PIRCHE's TxPredictor platform with post-transplant molecular monitoring using Natera's Prospera dd-cfDNA test. The partnership integrates PIRCHE's risk-stratification with dd-cfDNA monitoring to provide comprehensive data-driven patient immune status analysis across the transplant journey. Joint offerings planned for launch at the 2026 American Transplant Congress in June.

Strategic tierCoreTypeTechnology or Integration
Description

MatchX API integration partnership providing customers with next-generation antibody analysis utilizing epitope scoring. Integrates PIRCHE's advanced epitope matching technology with Werfen's comprehensive suite of transfusion and transplantation diagnostic solutions.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Partnership for educational webinars and professional education in transplant immunology and epitope matching technology.

4TTC (The Transplantation Society)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Partnership for educational content and professional development in transplantation medicine.

pirche.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mayo Clinic partnership for clinical validation and research collaboration in epitope matching for improved organ donor-recipient matching.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Collaborative webinar partnership for PIRCHE epitope matching education in kidney transplantation case studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Werfen's Transplant Diagnostics business (formerly Immucor/Lifecodes) provides HLA typing and antibody analysis products and the MatchX platform — a direct integration partner of PIRCHE and the closest broad incumbent competing in the same HLA lab workflow.

TypeBroad incumbent
Description

One Lambda, part of Thermo Fisher, is the dominant incumbent in HLA typing reagents and laboratory software for transplant diagnostics — offering overlapping functionality to PIRCHE within an established global installed base.

3Eurofins Transplant Genomics
TypeEmerging player
Description

Eurofins Transplant Genomics offers TruGraf blood-based graft monitoring for transplant patients — an emerging diagnostics player whose post-transplant monitoring focus overlaps with the PIRCHE companion-prognostics workflow.

TypeDirect peer
Description

Devyser develops HLA and transplant-related genetic testing kits and software — a listed PIRCHE integration partner operating in the same HLA diagnostics space with comparable transplant-center customers.

TypeRegional player
Description

Eurotransplant is the European organ allocation foundation referenced in PIRCHE research collaborations — a regional allocator whose HLA matching standards influence adoption of epitope-matching technologies like PIRCHE across European transplant centers.

TypeBroad incumbent
Description

CareDx is a transplant-focused diagnostics company with AlloSure dd-cfDNA and other post-transplant monitoring solutions, making it both a strategic complement and the most credible broad incumbent in the transplant decision-support market adjacent to PIRCHE.

7HistoTrac
TypeDirect peer
Description

HistoTrac provides HLA laboratory information management software used by transplant labs — listed alongside PIRCHE for custom HLA interface integrations, making it a direct peer and channel partner in the same HLA lab IT ecosystem.

TypeDirect peer
Description

GenDx provides HLA typing reagents and laboratory software (SBT, NGS, and analysis tools) used by transplant labs — directly overlapping with PIRCHE's HLA software footprint and listed as a PIRCHE integration and education partner.

TypeEmerging player
Description

Natera's Prospera dd-cfDNA test is the post-transplant monitoring arm of the PIRCHE companion-prognostics partnership, making Natera a strategic ally whose own transplant roadmap directly intersects with PIRCHE's pre-transplant risk offering.

TypeOthers
Description

Veloxis is a transplant-focused immunosuppression specialty pharmaceutical company — adjacent rather than directly competing, but a relevant peer for the transplant ecosystem in which PIRCHE's risk-stratification outputs inform immunosuppression decisions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PIRCHE

Transplant Immunology Softwarepirche.com

PIRCHE AG operates the TxPredictor platform, an AI-powered HLA epitope matching system that helps transplant centers predict donor-recipient immune compatibility, guide immunosuppression, and monitor post-transplant risk for solid organ and stem cell grafts.

What PIRCHE does

PIRCHE AG is a Berlin-headquartered digital diagnostics company founded in 2014 that builds the TxPredictor platform, described as an Immune Intelligence Platform for transplantation medicine. The company's core technology predicts how a recipient's immune system will recognize and respond to donor organ HLA epitopes using proprietary T-cell epitope matching (PIRCHE-I for CD8+ and PIRCHE-II for CD4+ responses) and B-cell epitope matching via the Snow algorithm, both powered by AI neural networks trained on HLA binding motifs. The platform processes genetic typing data on a high-performance cloud infrastructure and integrates with major HLA laboratory IT systems, offering six functional modules (RAMP, Tmem, Outcomes Prediction, Donor Selection, HSCT Search Profile) that support donor selection, immunosuppression management, and post-transplant surveillance for solid organ and stem cell transplantation, as well as emerging use cases in cell therapy and immuno-oncology.

The company commercializes TxPredictor as a subscription SaaS product through three access tiers (Routine, Research, Demo) sold via enterprise field sales targeting transplant centers and HLA laboratories globally. Distribution is augmented by integration partnerships — notably with Werfen (MatchX API), Natera (companion prognostics combining PIRCHE scores with Prospera dd-cfDNA monitoring), and Mayo Clinic for clinical validation — alongside educational partnerships with AST, TTC, and GenDx. PIRCHE cites more than 1 million real-world transplant cases processed and 200+ peer-reviewed publications supporting clinical utility. The company is privately held as a German Aktiengesellschaft, maintains a US regional office in Walpole, Massachusetts, has a small leadership team, and is actively soliciting external investment.

PIRCHE firmographics

Firmographics
Name
PIRCHE
Legal name
Pirche AG
Website
https://pirche.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
PIRCHE AG operates the TxPredictor platform, an AI-powered HLA epitope matching system that helps transplant centers predict donor-recipient immune compatibility, guide immunosuppression, and monitor post-transplant risk for solid organ and stem cell grafts.
Ownership category
akta.pro rank

PIRCHE industry classification

Industry
Product category
Transplant Immunology Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAMAL
Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • HLA epitope matching
  • Transplant immunology
  • Donor-recipient matching
  • Immunological risk assessment
  • Transplant compatibility software

Where PIRCHE is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

PIRCHE business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. TxPredictor Platform Subscription: PIRCHE operates as a SaaS platform (TxPredictor) providing molecular HLA epitope matching services to transplant centers and HLA laboratories. The platform is offered through a cloud-based subscription model with different access levels including routine access, research access, and demo access.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualPlatform access tiers for different user needs

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

PIRCHE product offering

Product offering

Core offering

PIRCHE develops and sells the TxPredictor platform, a cloud-based Immune Intelligence Platform that uses AI-supported immunological simulations to predict how a recipient's immune system will recognize and respond to donor organ HLA epitopes. The platform combines T cell epitope matching (PIRCHE-I and PIRCHE-II) with B cell epitope matching (Snow algorithm) to quantify pre-transplant immunologic risk, support donor selection, guide immunosuppression, and enable personalized post-transplant surveillance for solid organ and stem cell transplant centers and HLA laboratories.

Product overview

PIRCHE offers a platform-plus-modules architecture centered on the TxPredictor platform, the world's first Immune Intelligence Platform. The platform uses AI neural networks to analyze genetic HLA typing data and predict immunogenicity scores for transplant compatibility assessment. The product portfolio includes six modules: RAMP (Risk and Acceptable Mismatch Profile) for donor selection and immunosuppression management, Tmem for T-cell memory response modeling, Outcomes Prediction for clinical risk assessment, Donor Selection for multi-donor comparison, and HSCT Search Profile for stem cell donor identification. The platform integrates predictive PIRCHE immunogenicity scores with real-time dd-cfDNA injury detection through companion prognostics partnerships, transforming transplant care from reactive damage control to proactive precision surveillance.

Differentiator

Problem solved

Functional benefit

Products and services

  • TxPredictor The world's first Immune Intelligence Platform that merges genetic typing with AI-supported immunological simulations, enabling clinicians and HLA laboratories to make precise, personalized medical decisions for transplant patients. Runs on high-performance cloud infrastructure with real-time analysis, integration with major HLA vendors' software, absolute and relative immunologic risk quantification, and low turnaround time.
  • RAMP (Risk and Acceptable Mismatch Profile) Module supporting informed donor selection, immunosuppression management, and post-transplant monitoring by predicting epitope mismatches at the locus level. Allows users to evaluate how individual mismatches contribute to overall PIRCHE-T2 and PIRCHE-B scores and match donor populations to patients.
  • Tmem (T Memory) Module modeling T-cell memory responses that standard HLA testing cannot detect. Uses previous immunizer data to provide insight into potential post-transplant antibody risks by identifying HLA mismatches the immune system may have encountered before, distinguishing typical unacceptable mismatches from those associated with prior immune activation.
  • Outcomes Prediction Module (OPM) Module providing transplant teams with comprehensive understanding of factors influencing transplant outcomes by incorporating key clinical variables such as patient age, race, prior transplants alongside HLA molecular matching data. Available through the Early Access Program.
  • Donor Selection Module Tool supporting both solid organ and stem cell transplantation by allowing clinicians to compare multiple donors for a single patient using comprehensive immune profiling. Evaluates immunologic compatibility in real time with color-coded heatmaps highlighting which HLA mismatches most strongly contribute to total immunogenicity.
  • HSCT Search Profile Module designed for hematopoietic stem cell transplant teams to identify low-epitope-mismatched HLA combinations even without access to a full stem cell donor registry. Estimates likelihood of finding a donor with a low PIRCHE score and presents data in combined table and chart view.

Quantifiable outcome

  • Low PIRCHE score can help rule out development of harmful antibodies 94.2% of the time (Santos et al.)
  • +2 more outcomes

Companies that use PIRCHE

Customer profile

Segments2 records

Ideal customer profiles2 records

PIRCHE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature4 records

PIRCHE partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

  • Natera, Inc.flagshipStrategic or Co-development Partner · 19 June 2026Strategic collaboration to advance transplant medicine by combining pre-transplant immunological risk assessment using PIRCHE's TxPredictor platform with post-transplant molecular monitoring using Natera's Prospera dd-cfDNA test. The partnership integrates PIRCHE's risk-stratification with dd-cfDNA monitoring to provide comprehensive data-driven patient immune status analysis across the transplant journey. Joint offerings planned for launch at the 2026 American Transplant Congress in June.
  • Werfen (formerly Immucor)coreTechnology or IntegrationMatchX API integration partnership providing customers with next-generation antibody analysis utilizing epitope scoring. Integrates PIRCHE's advanced epitope matching technology with Werfen's comprehensive suite of transfusion and transplantation diagnostic solutions.
  • AST (American Society of Transplantation)minorGTM or Marketing PartnerPartnership for educational webinars and professional education in transplant immunology and epitope matching technology.
  • TTC (The Transplantation Society)minorGTM or Marketing PartnerPartnership for educational content and professional development in transplantation medicine.
  • Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic partnership for clinical validation and research collaboration in epitope matching for improved organ donor-recipient matching.
  • GenDxminorGTM or Marketing PartnerCollaborative webinar partnership for PIRCHE epitope matching education in kidney transplantation case studies.

Scale indicators2 records

Recent moves6 records

Expansion highlights7 records

PIRCHE competitors and assessment

Company assessment

Broad incumbents

  • Immucor (Werfen Transplant Diagnostics): Werfen's Transplant Diagnostics business (formerly Immucor/Lifecodes) provides HLA typing and antibody analysis products and the MatchX platform — a direct integration partner of PIRCHE and the closest broad incumbent competing in the same HLA lab workflow.
  • Thermo Fisher Scientific (One Lambda): One Lambda, part of Thermo Fisher, is the dominant incumbent in HLA typing reagents and laboratory software for transplant diagnostics — offering overlapping functionality to PIRCHE within an established global installed base.
  • CareDx: CareDx is a transplant-focused diagnostics company with AlloSure dd-cfDNA and other post-transplant monitoring solutions, making it both a strategic complement and the most credible broad incumbent in the transplant decision-support market adjacent to PIRCHE.

Emerging players

  • Eurofins Transplant Genomics: Eurofins Transplant Genomics offers TruGraf blood-based graft monitoring for transplant patients — an emerging diagnostics player whose post-transplant monitoring focus overlaps with the PIRCHE companion-prognostics workflow.
  • Natera: Natera's Prospera dd-cfDNA test is the post-transplant monitoring arm of the PIRCHE companion-prognostics partnership, making Natera a strategic ally whose own transplant roadmap directly intersects with PIRCHE's pre-transplant risk offering.

Direct peers

  • Devyser: Devyser develops HLA and transplant-related genetic testing kits and software — a listed PIRCHE integration partner operating in the same HLA diagnostics space with comparable transplant-center customers.
  • HistoTrac: HistoTrac provides HLA laboratory information management software used by transplant labs — listed alongside PIRCHE for custom HLA interface integrations, making it a direct peer and channel partner in the same HLA lab IT ecosystem.
  • GenDx: GenDx provides HLA typing reagents and laboratory software (SBT, NGS, and analysis tools) used by transplant labs — directly overlapping with PIRCHE's HLA software footprint and listed as a PIRCHE integration and education partner.

Regional players

  • Eurotransplant: Eurotransplant is the European organ allocation foundation referenced in PIRCHE research collaborations — a regional allocator whose HLA matching standards influence adoption of epitope-matching technologies like PIRCHE across European transplant centers.

Others

  • Veloxis Pharmaceuticals: Veloxis is a transplant-focused immunosuppression specialty pharmaceutical company — adjacent rather than directly competing, but a relevant peer for the transplant ecosystem in which PIRCHE's risk-stratification outputs inform immunosuppression decisions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

PIRCHE social profiles

Digital presence

PIRCHE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PIRCHE leadership team

Management profile

Number of profiles

Profiles6 records

PIRCHE funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PIRCHE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PIRCHE

What does PIRCHE do?

PIRCHE develops and sells the TxPredictor platform, a cloud-based Immune Intelligence Platform that uses AI-supported immunological simulations to predict how a recipient's immune system will recognize and respond to donor organ HLA epitopes. The platform combines T cell epitope matching (PIRCHE-I and PIRCHE-II) with B cell epitope matching (Snow algorithm) to quantify pre-transplant immunologic risk, support donor selection, guide immunosuppression, and enable personalized post-transplant surveillance for solid organ and stem cell transplant centers and HLA laboratories.

Is PIRCHE a public or private company?

PIRCHE is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PIRCHE founded?

PIRCHE was founded in 2014. It employs 11 to 50 people.

Where is PIRCHE based?

PIRCHE is headquartered in Berlin, Germany, in the Europe region.

How does PIRCHE make money?

One revenue line is on record: txPredictor Platform Subscription.

Who are PIRCHE's main competitors?

Broad incumbents on record are Immucor (Werfen Transplant Diagnostics), Thermo Fisher Scientific (One Lambda) and CareDx. Emerging players are Eurofins Transplant Genomics and Natera. Direct peers are Devyser, HistoTrac and GenDx. Eurotransplant is listed as a regional player. Veloxis Pharmaceuticals is listed as an others.

Does PIRCHE have an API?

No public API is recorded for PIRCHE.

What industry is PIRCHE in?

PIRCHE's product category is Transplant Immunology Software. Its primary akta.pro industry code is HLACAMAL, Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery). Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
01netPirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA MonitoringPirche AG announced a strategic collaboration with Natera, Inc. to advance transplant medicine by combining pre-transplant immunological risk assessment with post-transplant molecular monitoring using Natera's Prospera dd-cfDNA test. The partnership integrates Pirche's TxPredictor risk-stratification platform with Natera's Prospera test to provide transplant teams with comprehensive, data-driven analysis across the transplant journey. The companies plan to launch these combined offerings at the 2026 American Transplant Congress in June.Business Wire BlogPirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA MonitoringPirche AG announced a strategic collaboration with Natera, Inc. to advance transplant medicine by combining pre-transplant immunological risk assessment using Pirche's TxPredictor platform with post-transplant molecular monitoring via Natera's Prospera dd-cfDNA test. The partnership aims to enable comprehensive, data-driven analysis of patient immune status across the transplant journey to support more personalized immunosuppression therapies. The companies plan to launch joint educational efforts at the 2026 American Transplant Congress in June.FinancialContent Business PagePirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA MonitoringPirche AG has announced a strategic collaboration with Natera, Inc. to advance transplant medicine by combining pre-transplant immunological risk assessment with post-transplant molecular monitoring. The partnership integrates Pirche's TxPredictor platform with Natera's Prospera dd-cfDNA test to provide comprehensive, data-driven patient immune status analysis across the transplant journey. The companies plan to launch these combined offerings at the 2026 American Transplant Congress in June.MorningstarPirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA MonitoringPirche AG and Natera announced a partnership to combine pre-transplant risk stratification with post-transplant dd-cfDNA monitoring using Natera's Prospera test. The collaboration aims to personalize transplant care and optimize immunosuppression, with efforts kicking off at the 2026 American Transplant Congress.MarketScreenerPirche Ag and Natera, Inc. Announce Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant Dd-Cfdna MonitoringPirche AG and Natera announced a partnership to combine pre-transplant immunological risk assessment with post-transplant molecular monitoring using Natera's Prospera test. Pirche will drive customer education on its TxPredictor platform alongside Prospera results. The collaboration will launch at the 2026 American Transplant Congress in June.